AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17414047
Drug: Valacyclovir (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (1,000 mg/d for 5 days) plus prednisolone (VP)
Trial: 11434406
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum perforatum extract WS5572 (300 mg t.i.d.)
Trial: 8435016
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 micrograms twice a day via a spacer
Trial: 8435016
Drug: Budesonide 1600
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 1600 micrograms twice a day via a spacer and facemask
Trial: 29717032
Drug: Tanezumab (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab (pooled all treatment doses)
Trial: 29717032
Drug: Composite outcomes
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite outcomes (including WOMAC pain and rescue medication use)
Trial: 24876261
Drug: Intravenous tissue‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue‐type plasminogen activator (tPA) followed by endovascular therapy
Trial: 24876261
Drug: Intravenous tissue‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue‐type plasminogen activator (tPA) alone
Trial: 24876261
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy with routine use of general anesthesia
Trial: 24876261
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy without routine use of general anesthesia
Trial: 23865696
Drug: Gonadotropin initiation
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin initiation 3 weeks after GnRHa administration (Group A)
Trial: 23865696
Drug: Gonadotropin initiation
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin initiation 2 weeks after GnRHa administration (Group B)
Trial: 20528810
Drug: Pre-cessation nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-cessation nicotine patches and/or gum for 2 weeks prior to quit day
Trial: 18837607
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help treatments
Trial: 16652426
Drug: Intraarticular hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronic acid (HA) injections (20 mg/ml, 2 ml) administered once weekly for 3 weeks
Trial: 16652426
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) injections administered once weekly for 3 weeks
Trial: 10750292
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) after laparoscopic hysterectomy (LH) and/or bilateral salpingo‐oophorectomy (BSO)
Trial: 10750292
Drug: No estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No estrogen replacement therapy (control group)
Trial: 1424415
Drug: Single-dose sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sotalol (320 mg)
Trial: 1424415
Drug: Repeated sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated sotalol administration
Trial: 21824124
Drug: Laser dermabrasion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser dermabrasion followed by hydrocortisone 17-butyrate cream and narrowband UVB treatment
Trial: 21824124
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids and UVB alone
Trial: 21824124
Drug: UVB +
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVB + steroids alone group
Trial: 20216113
Drug: Computer-assisted dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted dosing (MAP-BE)
Trial: 15695140
Drug: Intravenous monteplase
RxNorm normalized name: Monteplase
DrugBank: Monteplase (DB12726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous monteplase followed by PCI
Trial: 11838852
Drug: Topical ice
RxNorm normalized name: Camphor Ice Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ice therapy, oral prednisone 30 mg PO tapered to 0 over 6 days, and colchicine 0.6 mg/day
Trial: 11838852
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received the same regimen without ice therapy
Trial: 11838852
Drug: Topical ice
RxNorm normalized name: Camphor Ice Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ice therapy
Trial: 10354080
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) ointment 0.005% (g/g)
Trial: 10354080
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) ointment
Trial: 2144866
Drug: Recombinant vaccine,
RxNorm normalized name: ebola (Zaire) recombinant vaccine, live, vero cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant vaccine, 10 micrograms in 1 ml intramuscularly
Trial: 2144866
Drug: Plasma-derived vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine, 2 micrograms in 0.1 ml intradermally
Trial: 2144866
Drug: Recombinant vaccine,
RxNorm normalized name: ebola (Zaire) recombinant vaccine, live, vero cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant vaccine, 1 microgram in 0.1 ml intradermally
Trial: 6137116
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists and pirenzepine
Trial: 17702837
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of [(13)C]bicarbonate during exercise at 45% Vo(2peak)
Trial: 17702837
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of [(13)C]bicarbonate during exercise at 65% Vo(2peak)
Trial: 8970411
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (0.625 mg/day conjugated estrogens or 2 mg/day estradiol)
Trial: 1455880
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (cisplatin and bleomycin) and surgery
Trial: 1455880
Drug: Pre-operative chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy, radiotherapy, and surgery
Trial: 3549312
Drug: Metoprolol (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100-200 mg daily)
Trial: 6380905
Drug: Methyldopa (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500-1000 mg daily)
Trial: 18563389
Drug: Half-molar sodium-lactate
RxNorm normalized name: SODIUM LACTATE 1/6 MOLAR INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-molar sodium-lactate (HL) solution, 10 ml kg BW(‐1) over 12 hours
Trial: 18563389
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate (RL) solution, 30 ml kg BW(‐1) over 12 hours
Trial: 10907144
Drug: Older couples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older couples presenting for conjoint therapy
Trial: 10907144
Drug: Younger couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Younger couples presenting for conjoint therapy
Trial: 1535447
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (0.5 mg nebulized)
Trial: 6146861
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide 80 mg/m2 on days 1‐14, intravenous methotrexate 32 mg/m2 on days 1 and 8, and intravenous fluorouracil 480 mg/m2 on days 1 and 8 (CMF), repeated every 28 days for twelve cycles.
Trial: 28364419
Drug: Modafinil treatment
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil treatment during abstinence
Trial: 27185725
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg IV infusion
Trial: 27185725
Drug: Labetalol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 0.25 mg/kg IV
Trial: 27185725
Drug: Saline 10
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 10 mL IV
Trial: 21971575
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg orally, once weekly
Trial: 21971575
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (IMN) 40 mg orally once daily
Trial: 8339624
Drug: Hydrocortisone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (10 mg/kg)
Trial: 3789327
Drug: Terbutaline slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline slow-release tablets (Bricanyl Depot), 5 mg twice daily
Trial: 3789327
Drug: Terbutaline ordinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline ordinary tablets (Bricanyl), 2.5 mg three times daily
Trial: 31469776
Drug: AS04-adjuvanted HPV-16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS04-adjuvanted HPV-16/18 vaccine (2-dose schedule)
Trial: 26907917
Drug: Passive-scattering proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive-scattering proton therapy (PT)
Trial: 24519012
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg of alcohol
Trial: 19393843
Drug: BUP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BUP infusion (0.4 microg/kg/h) + BUP boluses (0.15 microg/kg)
Trial: 19393843
Drug: MO infusion
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MO infusion (10 microg/kg/h) + MO boluses (5 microg/kg)
Trial: 19393843
Drug: BUP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BUP infusion (0.4 microg/kg/h) + MO boluses (5 microg/kg)
Trial: 19393843
Drug: MO infusion
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MO infusion (10 microg/kg/h) + BUP boluses (0.15 microg/kg)
Trial: 9882760
Drug: Temazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (20 mg p.o.)
Trial: 7721974
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg nitroglycerin (LDG)
Trial: 7721974
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg nitroglycerin (HDG)
Trial: 2199853
Drug: Ciclopiroxolamine globules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopiroxolamine globules, 100 mg nightly for six days
Trial: 2199853
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal tablets, 200 mg nightly for six days
Trial: 7014121
Drug: Oral propranolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol, 40 mg
Trial: 11006450
Drug: Ceftibuten 9
RxNorm normalized name: ceftibuten 90 MG in 5 mL Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten 9 mg/kg/day for 5 days
Trial: 11006450
Drug: Ceftibuten 9
RxNorm normalized name: ceftibuten 90 MG in 5 mL Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten 9 mg/kg/day for 10 days
Trial: 8839497
Drug: Cereal-based precooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal-based precooked porridge offered twice daily for 3 months (558-790 kJ/d)
Trial: 6436891
Drug: 195 mg
RxNorm normalized name: aspirin 195 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 195 mg caffeine
Trial: 3555083
Drug: 10 IU
RxNorm normalized name: Thyrotropin 10 IU Injection Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 IU of oxytocin in 10 ml of sodium chloride into the umbilical vein
Trial: 3555083
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of sodium chloride
Trial: 17081363
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Control, n = 25)
Trial: 12823568
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with antiepileptic drugs (AEDs)
Trial: 12823568
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring for dosage tailoring
Trial: 12823568
Drug: Newer antiepileptic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antiepileptic agents
Trial: 12823568
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine and treatment guidelines
Trial: 12823568
Drug: Patient-tailored AED
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-tailored AED selection and dose individualization
Trial: 12823568
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy in refractory epilepsies
Trial: 12823568
Drug: Novel antiepileptic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel antiepileptic drugs
Trial: 1430302
Drug: Surface electrocardiogram
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface electrocardiogram 2 hours after dose administration
Trial: 27329780
Drug: Pretreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with antifungal agents
Trial: 22202581
Drug: Whole-cell melanoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell melanoma vaccine (Canvaxin) plus Bacille Calmette-Guerin (BCG)
Trial: 20860537
Drug: Extra water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra water intake (EWI, an additional 30 ml water/kg body weight per day)
Trial: 10891628
Drug: Clozapine 12.5
RxNorm normalized name: clozapine 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 12.5 mg
Trial: 10891628
Drug: Clozapine 25
RxNorm normalized name: clozapine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 25 mg
Trial: 10891628
Drug: Clozapine 50
RxNorm normalized name: clozapine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 50 mg
Trial: 8752234
Drug: Atosiban (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (0.6 mg plus 30 micrograms/minute)
Trial: 8752234
Drug: Atosiban (6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (6.5 mg bolus plus 300 micrograms/minute)
Trial: 1362394
Drug: dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dopamine agonists
Trial: 1362394
Drug: l-deprenyl
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-deprenyl
Trial: 3891617
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg oral)
Trial: 20350164
Drug: Fractional-dose IPV
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional-dose IPV (0.1 mL, or 1/5 of a full dose) given intradermally
Trial: 20350164
Drug: Full-dose IPV
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose IPV given intramuscularly
Trial: 12709724
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil 200 mg twice daily for 10 days
Trial: 12709724
Drug: Cefditoren pivoxil
RxNorm normalized name: Cefditoren Pivoxil
DrugBank: Cefditoren (DB01066)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefditoren pivoxil 400 mg twice daily for 14 days
Trial: 26790793
Drug: Systemic Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic Tranexamic Acid (TXA) 15 mg/kg before and 10 mg/kg 1 hour after surgery
Trial: 26790793
Drug: Topical Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Tranexamic Acid (TXA) 2 g
Trial: 23168135
Drug: Backfill with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Backfill with hydroxyapatite-calcium triphosphate (HCT) biphasic compound
Trial: 16990664
Drug: GAD65 antibody
RxNorm normalized name: Recombinant human GAD65
DrugBank: rhGAD65 (DB04963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD65 antibody response
Trial: 12809069
Drug: Parenteral piracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral piracetam treatment
Trial: 12809069
Drug: Traditional meprobamat
RxNorm normalized name: Meprobamat
DrugBank: Meprobamate (DB00371)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional meprobamat therapy
Trial: 11014392
Drug: S-Caine patch
RxNorm normalized name: Comfort Caine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Caine patch coupled with a controlled heat-aided drug delivery (CHADD) patch
Trial: 9483483
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate therapy (Group I)
Trial: 9483483
Drug: No magnesium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No magnesium treatment (Group II)
Trial: 2751854
Drug: Ranitidine (H2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (H2 antagonist)
Trial: 326482
Drug: Practolol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (dose up to 800 mg daily)
Trial: 326482
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration of practolol
Trial: 31860328
Drug: Standard 6‐month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 6‐month course of tuberculosis treatment (180 days), dosed every other day (90 doses)
Trial: 30380221
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg · kg⁻¹ loading dose for 10 min, followed by 0.7 μg · kg⁻¹ · hr⁻¹ maintenance)
Trial: 30380221
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 μg · kg⁻¹ loading dose, followed by 1-2 μg · kg⁻¹ · hr⁻¹ maintenance)
Trial: 21643812
Drug: Atorvastatin (intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (intensive lipid-lowering therapy for 6 months)
Trial: 21643812
Drug: Pravastatin (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (moderate lipid-lowering therapy for 6 months)
Trial: 17301737
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2.5 mg tibolone
Trial: 17301737
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of tibolone (placebo, 0.3, 0.625, 1.25, or 2.5 mg/day for 26 cycles of 28 days)
Trial: 11304601
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream 1.5 g/10 cm2 applied for 2 to 5 hours
Trial: 11304601
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream 3 g/10 cm2
Trial: 11304601
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events (EMLA cream)
Trial: 1279611
Drug: Verapamil (120-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120-mg thrice daily)
Trial: 1279611
Drug: Diltiazem (60-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60-mg thrice daily)